search
Back to results

Effects of Exercise and Improved Nitric Oxide Bioavailability on Arteriovenous Fistula Maturation

Primary Purpose

End Stage Renal Disease

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Handgrip training
Nitroglycerin ointment
Sponsored by
Duke University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for End Stage Renal Disease

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Life expectancy of at least 6 months
  2. Chronic kidney disease with anticipated start of hemodialysis within six months or current hemodialysis dependence.
  3. Ability to understand and comply with the requirements of the entire study and communicate with the study team.
  4. Written informed consent using a document that has been approved by the Duke Human Institutional Review Board.
  5. If female and of childbearing potential (premenopausal and not surgically sterile) must have a negative pregnancy test and be willing to use contraception until completion of 8 weeks of intervention. This will include abstinence, barrier methods, hormones, or intra-uterine device.

Exclusion Criteria:

  1. Patients currently on medication that is contraindicated with nitropaste, including isosorbide nitrate therapy, nitroglycerin, minoxidil, or PDE inhibitors (i.e. Sildenafil).
  2. Patients with a diastolic blood pressure below 65 or a systolic blood pressure below 90.
  3. Patients with a history of illicit drug use in the previous 5 years.
  4. Patients who would require AVF placement before completion of the initial 4 weeks of intervention therapy
  5. Patients who are otherwise are not suitable for 8 weeks of handgrip training or nitropaste therapy.
  6. Patients under the 18 of age are not eligible for nitropaste interventions

Sites / Locations

  • Duke University Health System

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

No Intervention

Experimental

Experimental

Experimental

Arm Label

Control group

Handgrip training group

Nitroglycerin ointment group

Combined handgrip training /Nitroglycerin ointment group

Arm Description

Standard of care

Perform isometric handgrip exercises for 15 minutes twice per day for a total of 30 minutes

Apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly

Perform isometric handgrip exercises for 15 minutes twice each day for a total of 30 minutes and apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly

Outcomes

Primary Outcome Measures

Count of Participants With Mature Arteriovenous Fistula (AVF)
Use of AVF for dialysis for dialysis dependent participants, or fistula deemed mature based on physical exam in predialysis participants (diameter >6 mm, blood flow >600 ml by ultrasound or estimated by physical exam).

Secondary Outcome Measures

Count of Participants With a Patent Fistula
Determination that AVF is patent (has blood flow, no occlusion).
Count of Participants Using Their AVF for Dialysis
Successful use of AVF at 12 months in dialysis dependent patients. Not relevant in participants that are predialysis or that discontinue dialysis prior to AVF use.

Full Information

First Posted
June 12, 2014
Last Updated
June 16, 2017
Sponsor
Duke University
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT02164318
Brief Title
Effects of Exercise and Improved Nitric Oxide Bioavailability on Arteriovenous Fistula Maturation
Official Title
Effects of Exercise and Improved Nitric Oxide Bioavailability on Arteriovenous Fistula Maturation
Study Type
Interventional

2. Study Status

Record Verification Date
June 2017
Overall Recruitment Status
Terminated
Why Stopped
Lack of enrollment
Study Start Date
September 1, 2014 (undefined)
Primary Completion Date
February 18, 2016 (Actual)
Study Completion Date
March 10, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Duke University
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This project will examine if enhancing Nitric Oxide (NO) bioavailability increases the rates of arteriovenous fistula (AVF) maturation in end stage renal disease patients requiring vascular access for hemodialysis. To enhance NO bioavailability the study team will utilize a program of forearm exercise training, application of nitroglycerin ointment or both. Goals of this study are (A) to measure if recruited subjects can tolerate the intervention protocols, and determine if dependent variable measures, including surgery outcome, and measurement of physiologic and biologic markers, can be obtained; (B) To measure subject compliance and adherence rates for each of the intervention arms and testing visits; (C) To examine which intervention or combination of interventions demonstrates the strongest preliminary effects in order to estimate power for a pivotal intent to treat trial; and (D) explore group differences in clinical vascular markers and biologic markers in vein tissue.
Detailed Description
This project will examine if enhancing Nitric Oxide (NO) bioavailability increases the rates of arteriovenous fistula (AVF) maturation in end stage renal disease patients requiring vascular access for hemodialysis. To enhance NO bioavailability the study team will utilize a program of forearm exercise training, application of nitroglycerin ointment or both. Following entry into the study, approximately 4 weeks prior to surgery subjects will undergo a series of non-invasive tests of vascular function in the arm of fistula creation. Following this vascular function testing, subjects will follow the intervention treatment for 4 weeks. After 4 weeks of intervention treatment and prior to surgery, the vascular function analysis will be repeated to determine if the interventions had an effect on arm vascular function. Surgery to create the AVF will follow the second vascular function analysis. A discard sample of the vein used to create the AVF and a blood sample will be collected during surgery to assess potential biologic differences between intervention groups. The interventions will be continued until 4 weeks following surgery. Subjects will be followed to determine if the AVF matured and was successfully used for dialysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End Stage Renal Disease

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
11 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control group
Arm Type
No Intervention
Arm Description
Standard of care
Arm Title
Handgrip training group
Arm Type
Experimental
Arm Description
Perform isometric handgrip exercises for 15 minutes twice per day for a total of 30 minutes
Arm Title
Nitroglycerin ointment group
Arm Type
Experimental
Arm Description
Apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly
Arm Title
Combined handgrip training /Nitroglycerin ointment group
Arm Type
Experimental
Arm Description
Perform isometric handgrip exercises for 15 minutes twice each day for a total of 30 minutes and apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly
Intervention Type
Other
Intervention Name(s)
Handgrip training
Intervention Type
Drug
Intervention Name(s)
Nitroglycerin ointment
Other Intervention Name(s)
Nitropaste
Primary Outcome Measure Information:
Title
Count of Participants With Mature Arteriovenous Fistula (AVF)
Description
Use of AVF for dialysis for dialysis dependent participants, or fistula deemed mature based on physical exam in predialysis participants (diameter >6 mm, blood flow >600 ml by ultrasound or estimated by physical exam).
Time Frame
3 month post surgery to create AVF
Secondary Outcome Measure Information:
Title
Count of Participants With a Patent Fistula
Description
Determination that AVF is patent (has blood flow, no occlusion).
Time Frame
3 months post surgery
Title
Count of Participants Using Their AVF for Dialysis
Description
Successful use of AVF at 12 months in dialysis dependent patients. Not relevant in participants that are predialysis or that discontinue dialysis prior to AVF use.
Time Frame
12 months post surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Life expectancy of at least 6 months Chronic kidney disease with anticipated start of hemodialysis within six months or current hemodialysis dependence. Ability to understand and comply with the requirements of the entire study and communicate with the study team. Written informed consent using a document that has been approved by the Duke Human Institutional Review Board. If female and of childbearing potential (premenopausal and not surgically sterile) must have a negative pregnancy test and be willing to use contraception until completion of 8 weeks of intervention. This will include abstinence, barrier methods, hormones, or intra-uterine device. Exclusion Criteria: Patients currently on medication that is contraindicated with nitropaste, including isosorbide nitrate therapy, nitroglycerin, minoxidil, or PDE inhibitors (i.e. Sildenafil). Patients with a diastolic blood pressure below 65 or a systolic blood pressure below 90. Patients with a history of illicit drug use in the previous 5 years. Patients who would require AVF placement before completion of the initial 4 weeks of intervention therapy Patients who are otherwise are not suitable for 8 weeks of handgrip training or nitropaste therapy. Patients under the 18 of age are not eligible for nitropaste interventions
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeffrey H Lawson, MD/PhD
Organizational Affiliation
Duke Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke University Health System
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Effects of Exercise and Improved Nitric Oxide Bioavailability on Arteriovenous Fistula Maturation

We'll reach out to this number within 24 hrs